Abstract

Stem cell-derived islets (SC-islets) offer the potential to be an unlimited source of cells for disease modeling and the treatment of diabetes. SC-islets can be genetically modified, treated with chemical compounds, or differentiated from patient derived stem cells to model diabetes. These models provide insights into disease pathogenesis and vulnerabilities that may be targeted to provide treatment. SC-islets themselves are also being investigated as a cell therapy for diabetes. However, the transplantation process is imperfect; side effects from immunosuppressant use have reduced SC-islet therapeutic potential. Alternative methods to this include encapsulation, use of immunomodulating molecules, and genetic modification of SC-islets. This review covers recent advances using SC-islets to understand different diabetes pathologies and as a cell therapy.

Details

Title
Recent progress in modeling and treating diabetes using stem cell-derived islets
Author
Maestas, Marlie M 1 ; Bui, Maggie H 1 ; Millman, Jeffrey R 1   VIAFID ORCID Logo 

1  Roy and Diana Vagelos Division of Biology and Biomedical Sciences, Washington University School of Medicine , St. Louis, MO 63110 , United States 
Pages
949-958
Publication year
2024
Publication date
Oct 2024
Publisher
Oxford University Press
ISSN
21576564
e-ISSN
21576580
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/stcltm/szae059
ProQuest document ID
3192194123
Copyright
© The Author(s) 2024. Published by Oxford University Press. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.